Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ORMP, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Insulin | Type 2 Diabetes Mellitus | Phase 3 · NCT04606576 | Terminated |
| ORMD-0801 | Type 2 Diabetes Mellitus | Phase 3 · NCT06731075 | Not yet recruiting |
| ORMD 0801 | Brittle Type I Diabetes Mellitus | Phase 2 · NCT00867594 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ORMP holds $40.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ORMP files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Nadav Kidron President and CEO, Director |
Insider | 5,457,505 | 12.55% | 2026-11-12 |
| Aquamarine Financial (Cayman) Ltd | 5%+ holder (13G) | 2,653,567 | 6.10% | 2026-09-30 |
| Miriam Kidron Chief Scientific Officer, Director |
Insider | 2,149,554 | 4.94% | 2026-11-12 |
| Benjamin Shapiro Director |
Insider | 2,097,050 | 4.82% | 2026-11-12 |
| Joshua Hexter COO & CBO · +50,000 options |
Insider | 1,927,130 | 4.43% | 2026-11-12 |
| Avraham Gabay Chief Financial Officer |
Insider | 1,460,076 | 3.36% | 2026-11-12 |
| ORAMED PHARMACEUTICALS INC. 10% owner |
Insider | 1,250,363 | 2.88% | 2026-03-25 |
| Arie Mayer Director |
Insider | 242,259 | 0.56% | 2026-11-12 |
| Daniel Aghion Director |
Insider | 189,111 | 0.43% | 2026-11-12 |
| Yehuda Reznick Director |
Insider | 180,850 | 0.42% | 2026-11-12 |
| Leonard Sank Director |
Insider | 134,531 | 0.31% | 2025-06-05 |
Share count 43,485,942 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ORMP and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →